Cannabis Science completes selection of initial cannabis-based pharmaceutical for FDA clinical trials

Cannabis Science Inc. (NASD OTCBB: CBIS), a pharmaceutical cannabis company, is pleased to report to their shareholders that the choice of our initial cannabis-based pharmaceutical for FDA clinical trials has been made. The Company has reported several possible drugs for FDA clinical trials. Based on extensive studies, the Company has decided to contract with a group based in Colorado to handle the Company’s FDA filings. Appropriate announcements will be made when the contracts are finalized.

“We have decided to give this interim report due to the overwhelming interest we have been receiving in the US and around the World from existing and potential investors. In the next few days we will announce more specifics regarding our first FDA application.”

Dr. Robert Melamede, President & CEO Cannabis Science Inc., stated, “We have made great progress and this is just the beginning. We are in the final stages before Cannabis Science files with the FDA for clinical trials. There is a massive amount of Cannabis research that is available. Cannabis is one of the only drugs that have little or no negative side effects when used medically. We will request that the FDA consider this and other facts when examining our application. We have a great team of FDA experts and scientific minds to make sure that every step we take is inline with FDA requirements”

Richard Cowan, Cannabis Science Inc., CFO & Director stated, “We have decided to give this interim report due to the overwhelming interest we have been receiving in the US and around the World from existing and potential investors. In the next few days we will announce more specifics regarding our first FDA application."

Cannabis Science has accomplished and will be announcing shortly several critical steps to determine its FDA protocols and drug submission:

1. Successfully identified and negotiated medical cannabis growing operations to provide material for basic and clinical research.

2. Successfully identified and negotiated for several strains of medical cannabis for initial drug formulations.

3. Successfully identified cloning procedures to mass-produce exact strains in a controlled environment for compatibility with FDA standards.

4. Established analytical procedures for manufacturing reproducible, high-quality cannabis extracts in order to meet the anticipated high demand.

5. Identified and implementing several manufacturing opportunities for standardized production protocols for large-scale rapid mass production.

6. Successfully identified clinical trials facilities and doctors to handle clinical trials.

7. Negotiating several jurisdictional licensing and distribution agreements with potential partners around the World.

8. Identified and negotiating with key acquisitions for growth in various departments within the Company.